Belgian biotech company will use funding to start first-in-human clinical study for lead drug candidate in lung cancer Liege, Belgium, January 19, 2023 – DeuterOncology, a clinical-stage drug development company, today announces the closing of its €5.65 million ($6.1M) Series A financing, with participation from his.